Combination of Calcipotriene 0.005% Foam and Halobetasol Propionate 0.05% Foam in the Treatment of Scalp Psoriasis

Main Article Content

Alexis Young
Rhonda Schreiber


Psoriasis, Calcipotriene, Corticosteroid, Halobetasol


Abstract not available.


1. National Psoriasis Foundation. (2019, July 31). About Psoriasis. Retrieved from Psoriasis.Org : psoriasis.

2. American Academy of Dermatology. (n.d.). Psoriasis clinical guideline. Retrieved December 24, 2019, from quality/guidelines/ psoriasis.

3. Gudjonsson, J. E., & Elder , J. T. (2019). Chapter 28: Psoriasis. In S. Kang, M. Amagai , A. L. Bruckner, & et al (Eds.), Fitzpatrick's Dermatology (9 ed.). New York, NY: McGraw Hill.

4. Mayne Pharma. (2019, May 14 ). SORILUX Prescribing Information. Greenville, NC.

5. Mayne Pharma. (2019, April). Halobetasol Foam, 0.05% Prescribing Information. Greenville, N C.

6. Mayne Pharma. (2019). Data on file.

7. Van de Kerkhof, P.C. (2001). Therapeutic strategies: Rotational therapy and combinations. Clin Exp Dermatol, 26, 356.

8. Stein Gold, L., Horg an, A., Schreiber, R., & Ye, R. (2019). Determination of the In Vitro Chemical Compatibility of Calcipotriene Foam, 0.005%, in Combination with Halobetasol Proprionate Foam, 0.05%. Winter Clinical Dermatology Conference. Kawaii, HI: FRED.

Most read articles by the same author(s)

1 2 > >>